Oncology Research & Development

In Q4 2017, HS Pharmaceuticals will be initiating a new collaborative cancer research effort between The Medical University of South Carolina in Charleston, South Carolina and LifeArc (formerly The Medical Research Council) at Cambridge University in Cambridge, England. HS Pharmaceuticals has licensed technology from LifeArc that is focused on the silica nanoclusters application to T-cell…

Dental Health

Dental applications for both wound healing and bone regeneration show a great potential for HS Pharmaceuticals’ silicate-based nanoparticle technology. Proof of concept clinical pilot studies are being planned that should support our hypothesis for using our platform technology in improving Dental Health. The initial patent for these applications was filed with the US Patent and…